Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in Children and Young Adults With Recurrent or Progressive High Grade Glioma
NCT04323046Phase 1Active, not recruiting
- Start
- Oct 2020
- Primary completion
- Jun 2028
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of nivolumab in high-grade glioma (HGG). Primary endpoints: Percentage change in cell cycle-related genetic signature and Proportion of participants with treatment-related adverse events up to 2 years. Started Oct 2020; status: active, not recruiting.
02
Drugs
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT04323046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04323046.